Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03854032 · ClinicalTrials.gov registry record · Phase 2

Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck

A Phase 2 study of Squamous Cell Carcinoma and Oral Cavity Squamous Cell Carcinoma, sponsored by Thomas Jefferson University.

Active
Registry status
Phase 2
Development phase
45
Enrollment target
2
Study locations

NCT03854032 is a Phase 2 study of Squamous Cell Carcinoma and Oral Cavity Squamous Cell Carcinoma that is active but no longer recruiting, run by Thomas Jefferson University. The registered enrollment target is 45 participants, below the 103-participant average among 47 other Squamous Cell Carcinoma trials with a reported enrollment target (56% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03854032, a Phase 2 study of Squamous Cell Carcinoma and Oral Cavity Squamous Cell Carcinoma, is active but no longer recruiting, sponsored by Thomas Jefferson University.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
45 participants
Enrollment target
2
Study locations

Study Summary

This phase II trial studies how well nivolumab works, with or without BMS986205, in treating patients with stage II-IV squamous cell cancer of the head and neck. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. BMS986205 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving nivolumab with BMS986205 may work better than nivolumab alone in treating patients with squamous cell cancer of the head and neck.

Conditions Studied

Squamous Cell Carcinoma Oral Cavity Squamous Cell Carcinoma Lip Larynx Pharynx

Interventions

  • OTHER Questionnaire Administration
  • BIOLOGICAL Nivolumab
  • PROCEDURE Therapeutic Conventional Surgery
  • BIOLOGICAL IDO1 Inhibitor BMS-986205

Study Locations (2)

Ohio

  • Ohio State University - Columbus

Pennsylvania

  • Sidney Kimmel Cancer Center at Thomas Jefferson University - Philadelphia

Trial Details

FieldValue
Enrollment Target 45 participants
Start Date 2019-04-09
Est. Completion 2025-12-31
Phase Phase 2

Sponsor

Thomas Jefferson University

292 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03854032

The ClinicalTrials.gov registry entry for NCT03854032 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 103-participant average among 47 other Squamous Cell Carcinoma trials with a reported enrollment target (56% lower). The listed sponsor is Thomas Jefferson University, which has 292 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Squamous Cell Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Questionnaire Administration is the first listed.

NCT03854032 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Ohio, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT03854032 about?

NCT03854032 is a clinical study titled "Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck". This phase II trial studies how well nivolumab works, with or without BMS986205, in treating patients with stage II-IV squamous cell cancer of the head and neck. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with t...

What is the current status of trial NCT03854032?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2019-04-09. Estimated completion is 2025-12-31.

What conditions does trial NCT03854032 study?

This clinical trial studies the following conditions: Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma, Lip, Larynx, Pharynx.

What interventions are being tested in trial NCT03854032?

The interventions under investigation include: Questionnaire Administration (OTHER), Nivolumab (BIOLOGICAL), Therapeutic Conventional Surgery (PROCEDURE), IDO1 Inhibitor BMS-986205 (BIOLOGICAL).

Who is sponsoring clinical trial NCT03854032?

This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03854032 being conducted?

This trial has 2 study locations across Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Squamous Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Squamous Cell Carcinoma

All registered trials for this condition

Oral Cavity Squamous Cell Carcinoma

All registered trials for this condition

Ohio

All trials with a study site in Ohio

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.